Science and Research

New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy. As of January 2024, marketing authorization has been granted for four new indications in Europe, and regulatory approvals for other study regimens are expected. Because cost-effectiveness and reimbursement criteria for novel treatments often differ between European countries, access to emerging developments may lead to inequalities due to variations in recommended and available lung cancer care throughout Europe. This Series paper (i) highlights the clinical studies reshaping the treatment landscape in resectable early-stage NSCLC, (ii) compares and contrasts approaches taken by the European Medicines Agency (EMA) for drug approval to that taken by the United States Food and Drug Administration (FDA), and (iii) evaluates the differences in access to emerging treatments from an availability perspective across European countries.

  • Houda, I.
  • Dickhoff, C.
  • Uyl-de Groot, C. A.
  • Reguart, N.
  • Provencio, M.
  • Levy, A.
  • Dziadziuszko, R.
  • Pompili, C.
  • Di Maio, M.
  • Thomas, M.
  • Brunelli, A.
  • Popat, S.
  • Senan, S.
  • Bahce, I.

Keywords

  • Access to primary care
  • Adjuvant chemotherapy
  • Biomarkers
  • Disease-free survival
  • Europe
  • Humans
  • Immune checkpoint inhibitors
  • Lung neoplasms
  • Non-small-cell lung cancer
  • Protein kinase inhibitors
  • Surgery
  • United States
  • United States Food and Drug Administration
Publication details
DOI: 10.1016/j.lanepe.2024.100840
Journal: Lancet Reg Health Eur
Pages: 100840 
Work Type: Review
Location: TLRC
Disease Area: LC
Partner / Member: DKFZ, Thorax
Access-Number: 38476748

DZL Engagements

chevron-down